Schizophrenia is a life-shortening disease and life expectancy in patients may be 15–20
years shorter than in the general population, with increasing longevity gap over time …

Glioblastoma (GBM) is the most aggressive glial tumor of the central nervous system.
Despite intense scientific efforts, patients diagnosed with GBM and treated with the current …

Antipsychotic polypharmacy/drug combination treatment (APP) is a remarkably common
practice in the schizophrenia context, given the lack of general support in treatment …

Insomnia represents a significant public health burden, with a 10% prevalence in the
general population. Reduced sleep affects social and working functioning, productivity, and …

Glioblastoma (GBM) is associated with a very dismal prognosis, and current therapeutic
options still retain an overall unsatisfactorily efficacy in clinical practice. Therefore, novel …

Melanocyte cell death can lead to various melanocyte-related skin diseases including
vitiligo and leukoderma. Melanocytotoxic chemicals are one of the most well-known causes …

Objective Delirium is an acute, life-threatening neuropsychiatric disorder frequently
occurring among hospitalized patients. Antipsychotic medications are often recommended …

Cognitive deficits are a hallmark of schizophrenia, for which no convincing pharmacological
treatment option is currently available. Here, we tested spironolactone as a repurposed …

Background: Due to the embryotoxicity found in animal studies and scarce clinical data in
pregnant women, it is still controversial whether entecavir (ETV) and adefovir dipivoxil (ADV) …

Introduction Our objective was to conduct a systematic review and meta-analysis of adverse
effects on sleep in patients with schizophrenia receiving antipsychotic treatment. Methods A …